Jupiter Neurosciences, Inc. Common Stock Cash Flow-to-Debt Ratio
Jupiter Neurosciences, Inc. Common Stock cash flow-to-debt ratio. Jupiter Neurosciences, Inc. Common Stock (JUNS) has a Cash Flow-to-Debt Ratio of -0.56x as of June 2026, meaning its operating cash flow of $-2.29 Million could theoretically repay -1% of its total liabilities ($4.08 Million) in one year. Check JUNS cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Jupiter Neurosciences, Inc. Common Stock (2019–2025)
Cash flow-to-debt ratio of Jupiter Neurosciences, Inc. Common Stock from 2019 to 2025. Historical debt coverage capacity for Jupiter Neurosciences, Inc. Common Stock across 7 annual periods. Check Jupiter Neurosciences, Inc. Common Stock (JUNS) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Jupiter Neurosciences, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2019–2025)
Jupiter Neurosciences, Inc. Common Stock cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Jupiter Neurosciences, Inc. Common Stock. For the full cash flow conversion analysis, see cash flow conversion of Jupiter Neurosciences, Inc. Common Stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.73x | $-5.41 Million | $7.40 Million | ▲ +62.0% |
| 2024 | -1.93x | $-3.91 Million | $2.03 Million | ▼ -2283.0% |
| 2023 | -0.08x | $-480.95K | $5.95 Million | ▲ +52.2% |
| 2022 | -0.17x | $-1.25 Million | $7.38 Million | ▲ +43.0% |
| 2021 | -0.30x | $-1.74 Million | $5.85 Million | ▼ -396.4% |
| 2020 | -0.06x | $-254.78K | $4.26 Million | ▼ -110.1% |
| 2019 | -0.03x | $-142.95K | $5.02 Million | — |